Cargando…
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?
Eighty-six patients with tumour induced hypercalcaemia were randomised to 600, 900, 1200 or 1500 mg of intravenous clodronate, according to post hydration serum calcium levels. Sixty-seven were evaluable for response. The overall response rate was 49.3% (95% CI: 36.8–61.8) with no significant differ...
Autores principales: | Shah, S, Hardy, J, Rees, E, Ling, J, Gwilliam, B, Davis, C, Broadley, K, A'Hern, R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375352/ https://www.ncbi.nlm.nih.gov/pubmed/11953878 http://dx.doi.org/10.1038/sj.bjc.6600249 |
Ejemplares similares
-
Treatment of malignant hypercalcaemia with clodronate.
por: Percival, R. C., et al.
Publicado: (1985) -
Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
por: Ling, P. J., et al.
Publicado: (1995) -
Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate.
por: O'Rourke, N. P., et al.
Publicado: (1993) -
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
por: Purohit, O. P., et al.
Publicado: (1995) -
Meta-analysis of clodronate and breast cancer survival
por: Ha, T C, et al.
Publicado: (2007)